Incyclix Bio's potent and selective CDK2 inhibitor in first-in-human Phase 1/2 development.
Competing Products
Incyclix Bio
Incyclix Bio, LLC: A next-gen cell cycle control firm, advancing precision cancer treatments.
Founded
2020Incyclix Bio, LLC: A next-gen cell cycle control firm, advancing precision cancer treatments.
Incyclix Bio, LLC, founded with the mission to advance precision cancer treatments, focuses on next-generation cell cycle control. The company's vision is to develop therapies that specifically target the aberrant proliferation of cancer cells. Their lead product, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor, currently nearing clinical stage. Incyclix Bio aims to provide innovative solutions for patients suffering from various cancers, addressing a critical need in oncology.
Notable figures affiliated with Incyclix Bio include experienced leaders in biotechnology and oncology research. The company has garnered support from prominent investors in the biotech sector. Key achievements include the development of their lead compound, INX-315, which has shown promise in preclinical studies. Incyclix Bio's impact lies in its potential to offer new, targeted cancer therapies that could significantly improve patient outcomes by effectively controlling cell cycle progression in cancer cells.
Companies similar to Incyclix Bio include Allorion Therapeutics, Bio Green Med Solution, Incyte and Concarlo Holdings.
Incyclix Bio was founded in 2020.
Incyclix Bio's headquarters is located in Durham, NC, US.
Incyclix Bio's most recent funding round was for $30M (USD) in March 2022.
As of Mar 31, 2022, Incyclix Bio has disclosed funding of $36M (USD). Undisclosed round amounts are excluded.
Incyclix Bio has 6 employees as of Feb 5, 2024.
Concarlo Holdings
concarlo.com
